deltatrials
Completed OBSERVATIONAL NCT05464069

Safety of Nerivio in Pregnant Women With Migraine

A Retrospective Controlled Survey Study to Assess the Safety of Treating Migraine With Nerivio During Pregnancy and 3 Months Postpartum

Sponsor: Theranica

Conditions Migraine Pregnancy Related
Interventions Migraine Relief Nerivio
Updated 5 times since 2022 Last updated: Sep 14, 2025 Started: Aug 1, 2022 Primary completion: Nov 28, 2022 Completion: Dec 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Migraine and Pregnancy Related, this trial is completed. The trial is conducted by Theranica and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshotRecruiting~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2025 · 14 months · monthly snapshotCompleted~Nov 2025 – present · 8 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Nov 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Jan 2023 — Jul 2024 [monthly]

    Completed

    Status: Recruiting → Completed

  5. Sep 2022 — Jan 2023 [monthly]

    Recruiting

    First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Theranica
Data source: Theranica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations